PTD-DBM: Evidence, Mechanism, Dosing & Legal Status

PTD-DBM (Protein Transduction Domain-fused Dishevelled-Binding Motif) is a synthetic peptide engineered at Yonsei University to release a brake on the Wnt/β-catenin pathway and reactivate hair-follicle growth.12 Its target biology is genuinely well-validated and its preclinical results are striking; its proof in humans is nonexistent. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. PTD-DBM is an experimental research peptide with no approved human use and no completed human trials; it is sold as a "research chemical, not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published preclinical literature for completeness — never as recommendations. Consult a licensed clinician for any hair-loss concern.

What is PTD-DBM and how does it work?

PTD-DBM is a designed decoy peptide that fuses three functional parts: a protein-transduction domain (PTD) — a membrane-penetrating sequence that carries cargo across the lipid bilayer and stratum corneum — connected through a flexible linker to the Dishevelled-binding motif (DBM), the short C-terminal segment of CXXC5 that normally docks onto Dishevelled, plus a terminal lysine conjugated to FITC for visualization in the original work.2 Because it presents the Dvl-binding motif without the rest of CXXC5, it occupies Dishevelled and crowds out the full-length protein. The exact amino-acid sequence is detailed in the primary papers and the associated Yonsei patents but is not listed in secondary encyclopedic sources.512

The target is CXXC-type zinc-finger protein 5 (CXXC5), a negative-feedback regulator of Wnt/β-catenin signaling that acts by binding the PDZ domain of Dishevelled (Dvl).21 When CXXC5 is bound to Dvl, downstream Wnt signaling is dampened, β-catenin is not stabilized, and follicle-growth signals are suppressed. Critically for human relevance, CXXC5 is upregulated in the miniaturized hair follicles and arrector pili muscles of human balding scalp, and it suppresses alkaline-phosphatase activity and proliferation in human hair-follicle dermal-papilla cells.1 By competitively binding Dvl, PTD-DBM displaces CXXC5 and lifts the brake, producing stabilization and nuclear accumulation of β-catenin and transcription of Wnt target genes. In dermal fibroblasts the peptide dose-dependently raised β-catenin, α-SMA, collagen I and endothelin-1 while leaving the oncogene markers c-Myc and cyclin D1 unchanged, and Wnt activation was directly confirmed in Axin2-LacZ reporter mice.2 No formal pharmacokinetic data — plasma half-life, systemic absorption, metabolism or clearance — have been published; topical/local delivery is the only route studied.2

What is the evidence by indication?

The bottom line up front: there are no human RCTs, cohorts, or registered clinical trials of PTD-DBM for any indication. All efficacy evidence is animal and in-vitro, graded C; human relevance is inferred only from the target's dysregulation in balding human scalp and from cultured human dermal-papilla cells. The PubMed and ClinicalTrials.gov registries return no completed or registered human trials of the peptide as of 2026.3

The foundational dermatology study showed that disrupting the CXXC5-Dvl interaction with the competitor peptide activated Wnt/β-catenin and accelerated hair regrowth in mice, and that CXXC5⁻/⁻ knockout mice independently showed accelerated regrowth — genetically validating that removing the brake is sufficient.1 The same work demonstrated wound-induced hair follicle neogenesis: peptide treatment promoted formation of entirely new follicles within healing wound beds, a capability conventional hair drugs lack.1 In the wound-healing arm, CXXC5⁻/⁻ mice healed full-thickness dorsal wounds roughly 16-32% faster with about 6.3-fold higher fibroblast collagen deposition and over 4-fold higher β-catenin, and daily topical 100 µM PTD-DBM plus valproic acid 500 mM for 11 days achieved 42.8% re-epithelialization at day 3 versus 4.9% in controls, outperforming an EGF positive control — via an endothelin-1-dependent mechanism reversible by bosentan.2

A later mechanistic study placed CXXC5 inside the androgen cascade: DHT drives androgen-receptor-mediated PTGDS induction, then PGD2 and BMP signaling upregulate CXXC5, suppressing Wnt/β-catenin and miniaturizing follicles. Topical PTD-DBM (10 mM in 300 µL, every other day) reversed PGD2-induced suppression and partially restored DHT-induced suppression — but it was outperformed by the dual-action small molecule KY19382, which completely restored DHT-suppressed β-catenin by targeting both CXXC5 and GSK-3β.34

What doses appear in the literature?

Reported strictly as information, not a protocol — and there is no human dose at all. The route in every study is topical, applied to depilated or wounded dorsal mouse skin or used in cell and ex-vivo follicle culture; the PTD module is what allows skin penetration, and no injectable or systemic protocol has been published.2 The wound-healing study in C3H mice applied PTD-DBM 100 µM daily for 11 days, alone and combined with valproic acid 500 mM, with EGF 100 µM as a positive control.2 The androgenetic-alopecia study applied PTD-DBM 10 mM in 300 µL topically every other day in vivo, using PGD2 and DHT as challenge agents.3 Valproic acid acts downstream by inhibiting GSK-3β while PTD-DBM acts upstream at Dvl, so the two combine for greater effect — the same upstream-plus-downstream logic that later motivated the single dual-action molecule KY19382.14 Research vials are sold as lyophilized powder requiring reconstitution, with no validated human topical formulation, stability or sterility standard, and online topical use is grade-D anecdote against the products' own "not for human use" labeling.11

How safe is PTD-DBM?

Human safety data do not exist; the peptide has never completed a human trial, so its human adverse-event profile, immunogenicity, local irritation, absorption and long-term risk are unknown.3 The reassuring preclinical signal is limited: in the mouse wound study, no abnormal skin phenotype appeared after six months of treatment and the oncogenic markers c-Myc and cyclin D1 were not elevated in any group — encouraging, but mouse data over a short window, not a human safety database.2 The dominant theoretical concern is mechanistic: sustained Wnt/β-catenin activation is a proliferative, pro-angiogenic signal, and aberrant Wnt activity is implicated in several cancers, so chronic activation is a legitimate caution the short mouse studies cannot exclude.2 Pregnancy and lactation are cautioned on developmental and teratogenic grounds (Wnt is central to development; the stacked valproic-acid co-agent is a known teratogen), as is active or prior malignancy; no formal contraindications exist because there is no approved human use.2 In practice, research-chemical purity is an additional real hazard: vials sold "not for human use" can carry impurities, endotoxin, bacteria or heavy metals with no cGMP guarantee.11

What is the FDA and WADA status in 2026?

PTD-DBM is not an FDA-approved drug and has no USP monograph. It is not the active ingredient of any approved product and does not appear on the FDA's 503A or 503B compounding bulk-substance lists, so under the agency's 2024 revised compounding policy licensed pharmacies cannot lawfully compound it.68 Tellingly, it is absent from the July 23-24, 2026 Pharmacy Compounding Advisory Committee docket — which reviews BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax and Epitalon — underscoring that PTD-DBM sits entirely outside the regulated compounding pathway.7 Commercially it is available only through research-peptide vendors that explicitly label it "research chemical, not for human use," and the CXXC5-Dvl-disruption approach is covered by Yonsei University-originated patents.1112

For athletes the picture is clear despite the peptide not being named. The WADA Prohibited List's S0 class — Non-Approved Substances — captures any substance not approved by any governmental regulatory health authority for human therapeutic use and still under preclinical or clinical development.9 A preclinical, unapproved Wnt-activating peptide falls squarely under S0 and is therefore prohibited at all times for athletes in tested sport, with no Therapeutic Use Exemption.10 Distinct named hair or growth peptides such as TB-500 sit under S2; PTD-DBM is not in S2 but is still banned via the S0 catch-all.9

Bottom line. PTD-DBM pairs unusually well-validated target biology with a complete absence of human proof. CXXC5 is a real Wnt brake, it is demonstrably overexpressed in human balding scalp, and disrupting the CXXC5-Dishevelled interaction reactivates Wnt signaling to produce accelerated hair regrowth, true wound-induced follicle neogenesis and faster wound healing in mice. That is the honest ceiling of the evidence — grade C, animal and in-vitro only. A functional, root-cause read is favorable on the target, since addressing the DHT→PGD2→CXXC5 driver upstream is conceptually sound, but the molecule itself remains unproven in people and should be treated as experimental. Regulatory facts here are current as of June 2026; the July 23, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.